The impact of PLCO control arm contamination on perceived PSA screening efficacy
- 10 April 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cancer Causes & Control
- Vol. 23 (6), 827-835
- https://doi.org/10.1007/s10552-012-9951-8
Abstract
Purpose To quantify the extent to which a clinically significant prostate cancer mortality reduction due to screening could have been masked by control arm screening (contamination) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial. Methods We used three independently developed models of prostate cancer natural history to conduct a virtual PLCO trial. Simulated participants underwent pre-trial screening based on population patterns. The intervention arm followed observed compliance during the trial then resumed population screening. A contaminated control arm followed observed contamination during the trial then resumed population screening, while an uncontaminated control arm discontinued screening upon entry. We assumed a clinically significant screening benefit, applied population treatments and survival patterns, and calculated mortality rate ratios relative to the contaminated and uncontaminated control arms. Results The virtual trial reproduced observed incidence, including stage and grade distributions, and control arm mortality after 10 years of complete follow-up. Under the assumed screening benefit, the three models found that contamination increased the mortality rate ratio from 0.68–0.77 to 0.86–0.91, increased the chance of excess mortality in the intervention arm from 0–4 % to 15–28 %, and decreased the power of the trial to detect a mortality difference from 40–70 % to 9–25 %. Conclusions Our computer simulation models indicate that contamination substantially limited the ability of the PLCO to identify a clinically significant screening benefit. While the trial shows annual screening does not reduce mortality relative to population screening, contamination prevents concluding whether screening reduces mortality relative to no screening.This publication has 31 references indexed in Scilit:
- Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-upJNCI Journal of the National Cancer Institute, 2012
- IN THIS ISSUEJNCI Journal of the National Cancer Institute, 2012
- Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task ForceAnnals of Internal Medicine, 2011
- How Does Early Detection by Screening Affect Disease Progression?Medical Decision Making, 2011
- Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening TrialClinical Trials, 2010
- Calibrating disease progression models using population data: a critical precursor to policy development in cancer controlBiostatistics, 2010
- Prostate-Specific Antigen Screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer–RotterdamJNCI Journal of the National Cancer Institute, 2010
- Stage‐specific cancer incidence: An artificially mixed multinomial logit modelStatistics in Medicine, 2009
- Mortality Results from a Randomized Prostate-Cancer Screening TrialThe New England Journal of Medicine, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyThe New England Journal of Medicine, 2009